Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4926140 | 0.85 | SMN1; SMN2 (0.51) | SMN1; SMN2KMT2APOLBAPEX1SYK | |
| SCHEMBL9121815 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2ABCB1HSD17B10MEN1KMT2A | |
| SCHEMBL13152438 | 0.82 | MAPT (0.47) | SMN1; SMN2POLBAPEX1SYKCYP2C19 | |
| SCHEMBL12121090 | 0.82 | POLB (0.54) | POLBAPEX1SYKCYP2C19MAOA | |
| SCHEMBL6740652 | 0.82 | POLB (0.42) | MEN1KMT2APOLBAPEX1SYK | |
| SCHEMBL16142876 | 0.82 | NPC1 (0.45) | SMN1; SMN2MEN1KMT2APOLBAPEX1 | |
| SCHEMBL4658372 | 0.82 | POLB (0.50) | MEN1KMT2APOLBAPEX1 | |
| SCHEMBL13377342 | 0.82 | POLB (0.42) | SMN1; SMN2MEN1KMT2APOLBAPEX1 | |
| SCHEMBL28371006 | 0.81 | KCNMA1 (0.48) | SMN1; SMN2HSD17B10MEN1KMT2APOLB | |
| SCHEMBL16261170 | 0.79 | POLB (0.42) | SMN1; SMN2MEN1KMT2APOLBAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910274-B1 | PHENYL COMPOUNDS | LILLY CO ELI (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-1910274-B1 | PHENYL COMPOUNDS | LILLY CO ELI (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8076514-B2 | Dipeptidyl peptidase IV inhibitors; Type II diabetes; 2-[(2S,3R)-3-Amino-2-hydroxy-4-(2,4,5-trifluoro-phenyl)-butyl]-N-tert-butyl-4-chloro-benzamide Hydrochloride | ELI LILLY AND COMPANY (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076514-B2 | Dipeptidyl peptidase IV inhibitors; Type II diabetes; 2-[(2S,3R)-3-Amino-2-hydroxy-4-(2,4,5-trifluoro-phenyl)-butyl]-N-tert-butyl-4-chloro-benzamide Hydrochloride | ELI LILLY AND COMPANY (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076514-B2 | Dipeptidyl peptidase IV inhibitors; Type II diabetes; 2-[(2S,3R)-3-Amino-2-hydroxy-4-(2,4,5-trifluoro-phenyl)-butyl]-N-tert-butyl-4-chloro-benzamide Hydrochloride | ELI LILLY AND COMPANY (US) | 2011-12-13 | — | — | US | disclosed |
| US-20080221217-A1 | Phenyl Compounds and Their Use in the Treatment of Type II Diabetes | ELI LILLY AND COMPANY | 2008-09-11 | — | — | US | disclosed |
| US-20080221217-A1 | Phenyl Compounds and Their Use in the Treatment of Type II Diabetes | ELI LILLY AND COMPANY | 2008-09-11 | — | — | US | disclosed |
| US-20080221217-A1 | Phenyl Compounds and Their Use in the Treatment of Type II Diabetes | ELI LILLY AND COMPANY | 2008-09-11 | — | — | US | disclosed |
| EP-1910274-A1 | PHENYL COMPOUNDS | Eli Lilly and Company (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007015807-A1 | PHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015807-A1 | PHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20050038019-A1 | Hydroxy substituted amides for the treatment of alzheimer's disease | PHARMACIA & UPJOHN | 2005-02-17 | — | — | US | disclosed |
| US-5719287-A | Intermediates for inhibitors of HIV protease and method of preparation thereof | ELI LILLY AND COMPANY (US) | 1998-02-17 | — | — | US | disclosed |
| US-5508407-A | TREATING OR PREVENTING INFECTION BY HIV | ELI LILLY AND COMPANY (US) | 1996-04-16 | — | — | US | disclosed |
| EP-0526009-A1 | Inhibitors of hiv protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221217-A1 | Phenyl Compounds and Their Use in the Treatment of Type II Diabetes | DPP4, GPR119, SLC5A2 | SMN1; SMN2 3850/4885ABCB1 81/4885HSD17B10 147/4885 |
| US-20050038019-A1 | Hydroxy substituted amides for the treatment of alzheimer's disease | BACE1, APP, BACE2 | SMN1; SMN2 2033/4885ABCB1 1304/4885HSD17B10 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.